16 Jul 2026 04:51:43 ET │ 11 pages Ascletis Pharma (1672.HK) ASC30 global Phase III Cleared to Start; Broader pipeline strengthen BD optionality CITI'S TAKE On July 16th, we hosted a business update call with Ascletis founder & Chairman Dr. Jinzi Wu. ASC30's global Phase III has been cleared by FDA, with initiation now set for September 2026, and completion targeted July 2028, positioning it as a potential second-to-market oral small molecule GLP-1 globally. The company is simultaneously developing ASC48, t ...

16 July 2026 | 12:49PM HKT Equity Research Ascletis Pharma Inc. (1672.HK): ASC30 global ph3 scheduled in September; eyes on dosing strategy / BD updates Global ph3 cleared for ASC30: On July 16th, we attended a business update call for Ascletis, during which mgmt shared the latest update on the global development plan for ASC30 (oral GLP-1). The global ph3 trial for ASC30 in obesity was recently cleared by the FDA, and is scheduled to initiate this September, which is in accordance with the previous guidanc ...